Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 17/20 | 0.42 |
| ▸ | HCRTR2 | O43614 | 5/20 | 0.41 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.41 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9899416 | 0.87 | HCRTR1 (0.43) | HCRTR1HCRTR2OPRK1 | |
| SCHEMBL3390036 | 0.86 | HCRTR1 (0.39) | HCRTR1HCRTR2PRMT5GPR119 | |
| SCHEMBL1119975 | 0.83 | HCRTR1 (0.49) | HCRTR1HCRTR2OPRK1 | |
| SCHEMBL9928401 | 0.81 | HCRTR1 (0.51) | HCRTR1HCRTR2OPRK1PRMT5 | |
| SCHEMBL10002349 | 0.81 | SYK (0.45) | HCRTR1HCRTR2OPRK1 | |
| SCHEMBL8007000 | 0.79 | HCRTR1 (0.47) | HCRTR1HCRTR2OPRK1PRMT5 | |
| SCHEMBL8007405 | 0.79 | HCRTR2 (0.60) | HCRTR1HCRTR2OPRK1PRMT5KMT2A | |
| SCHEMBL9928404 | 0.78 | HCRTR1 (0.43) | HCRTR1HCRTR2 | |
| SCHEMBL9928407 | 0.74 | CYP3A4 (0.37) | HCRTR1HCRTR2OPRK1PRMT5KMT2A | |
| SCHEMBL9899048 | 0.74 | HCRTR1 (0.72) | HCRTR1HCRTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120149711-A1 | PIPERIDINE DERIVATIVES USED AS OREXIN ANTAGONISTS | GLAXO GROUP LIMITED | 2012-06-14 | — | — | US | disclosed |
| US-20120149711-A1 | PIPERIDINE DERIVATIVES USED AS OREXIN ANTAGONISTS | GLAXO GROUP LIMITED | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149711-A1 | PIPERIDINE DERIVATIVES USED AS OREXIN ANTAGONISTS | HCRTR2, HCRTR1, OXTR | HCRTR1 2/4885HCRTR2 1/4885OPRK1 46/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.